Samantha Semenkow
Stock Analyst at Citigroup
(0.76)
# 3,756
Out of 4,835 analysts
43
Total ratings
25.71%
Success rate
-20.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Samantha Semenkow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Maintains: Buy | $8 → $4 | $1.08 | +270.37% | 3 | May 15, 2025 | |
| ARGX argenx SE | Maintains: Buy | $796 → $803 | $560.66 | +43.23% | 6 | May 9, 2025 | |
| GPCR Structure Therapeutics | Initiates: Buy | $60 | $24.17 | +148.24% | 1 | May 2, 2025 | |
| BIOA BioAge Labs | Maintains: Neutral | $7 → $5 | $3.88 | +28.87% | 3 | Mar 24, 2025 | |
| SLRN Acelyrin | Maintains: Neutral | $6 → $3 | $2.17 | +38.57% | 2 | Jan 7, 2025 | |
| VYGR Voyager Therapeutics | Initiates: Buy | $12 | $3.29 | +265.30% | 1 | Dec 2, 2024 | |
| CPRX Catalyst Pharmaceuticals | Maintains: Buy | $27 → $31 | $23.82 | +30.17% | 2 | Aug 9, 2024 | |
| SANA Sana Biotechnology | Maintains: Buy | $8 → $15 | $1.72 | +772.09% | 2 | Aug 9, 2024 | |
| SNSE Sensei Biotherapeutics | Reinstates: Buy | $4 | $0.34 | +1,092.96% | 2 | Jun 3, 2024 | |
| LRMR Larimar Therapeutics | Maintains: Buy | $10 → $14 | $2.00 | +601.75% | 6 | May 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 | $1.38 | +627.27% | 2 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $15 | $1.42 | +956.34% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $30 | $1.77 | +1,594.92% | 2 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $72 | $37.05 | +94.33% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $50 | $14.07 | +255.37% | 3 | Sep 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $56 | $17.69 | +216.56% | 3 | Aug 9, 2023 |
Allogene Therapeutics
May 15, 2025
Maintains: Buy
Price Target: $8 → $4
Current: $1.08
Upside: +270.37%
argenx SE
May 9, 2025
Maintains: Buy
Price Target: $796 → $803
Current: $560.66
Upside: +43.23%
Structure Therapeutics
May 2, 2025
Initiates: Buy
Price Target: $60
Current: $24.17
Upside: +148.24%
BioAge Labs
Mar 24, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $3.88
Upside: +28.87%
Acelyrin
Jan 7, 2025
Maintains: Neutral
Price Target: $6 → $3
Current: $2.17
Upside: +38.57%
Voyager Therapeutics
Dec 2, 2024
Initiates: Buy
Price Target: $12
Current: $3.29
Upside: +265.30%
Catalyst Pharmaceuticals
Aug 9, 2024
Maintains: Buy
Price Target: $27 → $31
Current: $23.82
Upside: +30.17%
Sana Biotechnology
Aug 9, 2024
Maintains: Buy
Price Target: $8 → $15
Current: $1.72
Upside: +772.09%
Sensei Biotherapeutics
Jun 3, 2024
Reinstates: Buy
Price Target: $4
Current: $0.34
Upside: +1,092.96%
Larimar Therapeutics
May 22, 2024
Maintains: Buy
Price Target: $10 → $14
Current: $2.00
Upside: +601.75%
May 16, 2024
Upgrades: Buy
Price Target: $10
Current: $1.38
Upside: +627.27%
May 9, 2024
Maintains: Buy
Price Target: $16 → $15
Current: $1.42
Upside: +956.34%
Apr 4, 2024
Maintains: Buy
Price Target: $26 → $30
Current: $1.77
Upside: +1,594.92%
Dec 8, 2023
Initiates: Buy
Price Target: $72
Current: $37.05
Upside: +94.33%
Sep 27, 2023
Maintains: Buy
Price Target: $33 → $50
Current: $14.07
Upside: +255.37%
Aug 9, 2023
Maintains: Buy
Price Target: $60 → $56
Current: $17.69
Upside: +216.56%